Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU1-96P refers to a pseudogene related to U1 small nuclear RNA, specifically termed "RNA, U1 small nuclear 96, pseudogene." Unlike canonical U1 small nuclear RNA (which plays an essential role in the spliceosome as part of pre-mRNA splicing), RNU1-96P is considered a non-functional pseudogene located at chromosome 3p24[3]. Pseudogenes such as RNU1-96P contain sequences similar to active snRNA genes but bear mutations or structural changes that prevent them from producing a functional RNA or protein product[2]. Most pseudogenes including RNU1-96P do not have established biological functions or roles as therapeutic targets. However, a few U1-like snRNA pseudogenes have been shown in some contexts to generate variant snRNAs that might be processed into stable RNAs and possibly incorporated into ribonucleoprotein complexes, though there is no evidence that RNU1-96P itself is functional or disease-related[2][3]. U1 snRNA itself is part of the major spliceosome complex, but RNU1-96P does not encode a functional snRNA and thus is not considered a drug target or biomarker. Key points: - RNU1-96P is a **pseudogene** for U1 snRNA, classified as a non-coding RNA. - It is **not a therapeutic target** (such as a receptor, enzyme, or transporter). - There is **no evidence of a direct biological function, disease association, drug interaction, or role as a biomarker** for RNU1-96P[2][3]. - This locus is **not functionally interchangeable** with the canonical U1 small nuclear RNA gene (RNU1-1 or related functional paralogs)[2]. - There is nothing apparently misspelled, but its inclusion as a "target molecule/receptor" is **incorrect**, as this pseudogene is not actionable in the context of drug targeting or biomarker use[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 96, pseudogene (RNU1-96P).